New Opportunities: Pharmaceutical Innovation and Investment in the Post-Epidemic Era.

On the evening of September 27th, the 5th Satellite Conference, co-hosted by Yuanming Capital, Yuanxuan Origin, Yanfeng Capital and Yasheng Pharmaceuticals, was successfully held in Suzhou on the occasion of the China Pharmaceutical Innovation and Investment Conference (here is called the "Venture Capital Conference").
the elites in various fields of the pharmaceutical industry have been reunited and have a pleasant dialogue on the theme of "Pharmaceutical Innovation and Investment in the Post-Epidemic Era".
as one of the annual "classic projects" that co-prosperity with the Venture Capital Conference, the 5th Satellite Conference has once again received the full attention of the pharmaceutical and investment communities, attracting more than 300 people from the industry to attend.
this satellite conference form innovation, with a more relaxed and free atmosphere to create a medical experts, investment elites, media friends in-depth exchange of ideas feast.
Song Ruixuan Executive Director of the China Pharmaceutical Innovation Promotion Association First of all, on behalf of the China Pharmaceutical Promotion Association to give you the support of the Venture Capital Conference, I hope you can find their own partners on this platform, play the role of this platform.
also hope that our "China's most investment value biomedical innovation city evaluation" project can provide cities around the details of their own development value and development positioning reference, play a positive role in promoting.
this year's venture capital conference under the influence of the new crown epidemic can successfully attract many domestic and foreign industry expert leaders to attend, indicating that China's pharmaceutical innovation and development is booming.
more and more people, there are many new faces, representing our team is growing, we are all witnesses of China's pharmaceutical innovation and reform and development! Tian Yuanming Capital Founding Partner thanks every guest and friend who was present today.
In the past five years, Yuanming Capital has invested in a large number of very good enterprises in the biopharmaceutical industry, such as Baiji Shenzhou, Yasheng Pharmaceuticals, Changfeng Pharmaceuticals, Pharmaceutical Ming Juno, Ano Pharmaceuticals and so on.
We started to invest in innovative drugs in 2015, the domestic is still in a less dare to invest in the stage, but Yuanming adhere to this road, with the industry to grow together, so far has achieved better results.
we have also invested in Meisheng Medical, the world's number one small proton knife company, and completed a strategic holding in 2018, actively promoting the arrival of the world's most cutting-edge proton technology at home.
I am also the chairman of Meisheng Medical Group, Meisheng Medical has become one of the pharmaceutical enterprises located in Suzhou, the future will help high-end medical device industry clusters in Suzhou continued to grow and develop.
In the post-epidemic era, global medical investment will be further strengthened, which will lead to a range of development opportunities, including innovative drugs, medical devices and other health management needs, and we will fully grasp such development opportunities to create satisfactory returns for investors."
welcome friends from outside Suzhou to come to Suzhou at this time of year and make new partners at this event.
As an individual who really participated in the investment of innovative drugs 13 years ago, I have witnessed the development process of china's whole pharmaceutical investment over the years, and it is very lonely to invest in innovative drugs in 2007 and 2008.
2015, When China entered the new year of innovative drugs, we found more and more friends together.
2017, the industry's heat has reached an all-time high, and the ranks are already a bit crowded.
the new crown outbreak in 2020 has added a firewood, so that the investment industry more fire, this year many projects have reached the point of grabbing quotas.
is such heat a good thing or a bad thing? From a large ecological point of view is certainly a good thing, the whole of China's innovative medicine ecology is more and more rich, more and more people involved, the development of the entire industry more and more promising, a large number of companies in the middle of more opportunities to come out.
but from an investment point of view, I think the heat may actually be a little too much.
Yuanxuan origin this year in the new drug research and development investment strategy made a larger adjustment.
In the five years from 2015 to 2020, 70 percent of us invested in innovative drugs, but this year 40 percent of the new fund invested in innovative drugs and invested in truly innovative drugs, such as the first-in-class program.
as in the past, large platform projects, big opportunities are not so many, into the "real innovation" stage.
Chairman Zhu Jinqiao, Welcome to tonight's satellite meeting.
you also saw that the scene is very active, everyone is in high spirits.
as President Song Ruixuan said, our satellite conference is the star satellite meeting in the annual pharmaceutical investment conference, the most popular and the most bright spot.
of course, I would like to thank everyone for the show.
we are in Shenzhen, Shekou, time is money, so I do not want to waste too much of everyone's time.
today's theme is "pharmaceutical innovation and investment in the post-epidemic era", then I would like to say that medical investment, especially biopharmaceutical investment, should forget the outbreak, to open up the epidemic fog! Why do you say that? Because the outbreak is a once-in-a-century event, the impact on the pharmaceutical industry is not the norm, investment in biopharmaceuticals to adhere to real value investment, both to maintain a high degree of focus, but also need insight into the future forward-looking.
whether there is an outbreak or not, only adhere to the original, vigorous innovation, adhere to the main channel of enterprises can go long-term, stand out.
in the fog of the epidemic, entrepreneurs and investors admicated should be well aware of this.
For example, we invested in Shanghai and Yuan biological last May, is a virus carrier enterprises, when the outbreak has not yet appeared, but we are already in the layout, to this year has been cast twice in a row.
, as recently as July and August, everyone knew that meta-organisms were vectors of the virus and an essential part of vaccine production.
, these are to be laid out in advance, not the outbreak came, what hot to do, that is speculation, not investment.
gene therapy and cell therapy in the future will generally be about a year or two ahead of schedule, not too far ahead.
Mr. Ren Zhengfei said, "One step ahead is a pioneer, just one step ahead."
, what is pharmaceutical investment in the post-epidemic era? With or without the outbreak, our investment logic will not change, focus, professionalism, stick to the main channel.
's always about whether pharmaceutical companies have core technology, good teams, innovative genes, there's nothing about the outbreak," he said.
recently, Zhong Li, of Farmer' Springs, said that water can't come in without money.
, to make high-quality aquatic products, all need 20 years of accumulation, not to mention biomedicine? So while the impact of the outbreak exists, the opportunity is reserved for those who are prepared and those who are focused.
Yang Dajun Yasheng Pharmaceutical Chairman and CEO of this year's outbreak of the world's new crown has brought shocks and impacts to all walks of life, but also to our biopharmaceutical industry has brought opportunities.
can be said to further highlight that biomedicine is a forever sunrise industry, so that China and even the world's government departments pay more attention to biomedicine, a large amount of capital also poured into the industry's investment path.
2015 was the first year of China's innovative medicine because of two changes.
first, the DRUG administration made three decisions: first, to redefine the concept of "new drugs".
until 2015, China was a class 1 new drug without a drug, and after a redefinition, there was no chinese or foreign drug to be called a new drug.
second, the implementation of drug market licensing system (MAH).
third, the implementation of drug consistency evaluation.
three points ushered in a new era for the development of innovative drugs in China.
followed by the emergence of the new three boards, for no profit, no products, no income enterprises to provide a listing platform.
the new three boards did not meet expectations in the end, but at least provided capital with an exit mechanism.
so it was not easy to have the foresight and the courage to invest in innovative drugs in 2014, and the three institutions here were able to invest in ASMA at that time, facing a lot of pressure, uncertainty and risk.
I would like to thank our A-round investors Yuanming Capital, Yuan Yuyuan Origin and Yanfeng Capital in particular.
compared with last year, Asah Pharmaceuticals has also made a new change this year - as a "listed company" to meet you again on the satellite.
we successfully listed in Hong Kong on October 28, 2019, and we would like to thank China Biopharmaceuticals in investing US$20 million to become our cornerstone investor.
the future, we continue to move forward hand in hand.
meeting site also has a number of investment elite, business leaders of old and new friends warm interaction, thinking about the future! Negotiating Time Network Source: Network Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.